Drug Approval | April 22, 2026
US FDA okays Merck's new once-daily HIV pill
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Its a major breakthrough for women’s ovarian cancer care in Europe
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
Merck emphasized the broader significance of the findings
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
Subscribe To Our Newsletter & Stay Updated
